Abbott's financial report is poor. The annual revenue was 54.3 billion, a decrease of 6%, but operating costs increased by 13% and R&D expenses increased by 9% to reach 7 billion, but this is a good thing. The most serious increase was a 48% increase in acquisition costs to 5.3 billion, a 4.5-fold increase in asset write downs to 4.2 billion, resulting in a 60% to 4.9 billion decrease in profits.